Anastasios (Tassos) Dimou, MD, shares advice from managing patients with non–small cell lung cancer who experience disease progression following therapy.
Anastasios (Tassos) Dimou, MD
Advertisement
Articles by Anastasios (Tassos) Dimou, MD
Anastasios (Tassos) Dimou, MD, shares advice from managing patients with non–small cell lung cancer who experience disease progression following therapy.
Anastasios (Tassos) Dimou, MD, discusses emerging treatment options in BRAF-positive lung cancer.
Anastasios (Tassos) Dimou, MD, discusses emerging treatment options in BRAF-positive lung cancer.
Anastasios (Tassos) Dimou, MD, discusses the progress made in the treatment of patients with ALK-positive lung cancer.
Anastasios (Tassos) Dimou, MD, discusses the limitations of tumor mutational burden as a biomarker in lung cancer.
Advertisement
Latest Updated Articles
Dr. Dimou on Managing Disease Progression in NSCLCMay 21st 2020
Dr. Dimou on Progress Made in ALK+ Lung Cancer TreatmentApril 14th 2020
- Dr. Dimou on Managing Disease Progression in NSCLC
May 21st 2020
Advertisement
Advertisement
Trending on OncLive
1
FDA CTGTAC Votes in Favor of RP1/Nivolumab Data in Advanced Melanoma
2
FDA Grants Priority Review to Subcutaneous Amivantamab in Head and Neck Cancer
3
FDA Awards Orphan Drug Designation to Enzomenib for ALL
4
Dr Barot on the FDA Approval of Palbociclib/Trastuzumab ± Pertuzumab in HER2+ Breast Cancer
5